Welcome to our dedicated page for Iteos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on Iteos Therapeutics stock.
iTeos Therapeutics news covers the former clinical-stage biopharmaceutical company's immuno-oncology pipeline, including programs aimed at tumor immunology and immunosuppressive pathways such as the TIGIT/CD226 axis and the adenosine pathway. Recurring updates include clinical data for belrestotug combinations, EOS-984, EOS-215 and other preclinical programs, financial results, conference presentations and collaboration developments.
Recent company developments also include the termination of the belrestotug development program, a strategic review and wind-down of operations, and completed corporate-status changes tied to the acquisition of the company's common stock, Nasdaq delisting and Exchange Act deregistration.
iTeos Therapeutics (ITOS) reported its Q3 2022 results, highlighting the initiation of a Phase 2 trial for anti-TIGIT monoclonal antibody EOS-448 combined with GSK’s Jemperli in first-line metastatic non-small cell lung cancer (NSCLC).
The company holds a strong cash position of $752 million, projected to sustain operations into 2026. R&D expenses rose to $23.9 million, largely due to heightened clinical activities. Notably, net income declined to $1 million, or $0.03 per share, compared to $69.6 million in the same quarter last year.
iTeos Therapeutics (ITOS) has initiated patient enrollment for two Phase 2 trials focusing on advanced cancer treatments. The trials evaluate the efficacy of EOS-448, an anti-TIGIT monoclonal antibody, in combination with GSK’s Jemperli for head and neck squamous cell carcinoma, and inupadenant, an adenosine A2A receptor antagonist, with chemotherapy for non-small cell lung cancer. As of June 30, 2022, the company reported a cash balance of $792 million, sufficient to support operations through 2026. Recent R&D expenses have risen to $26.9 million, reflecting increased clinical activities.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced that its CEO, Michel Detheux, will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:00 a.m. ET. The topic will focus on opportunities and challenges in immuno-oncology.
A live webcast can be accessed on the company's website, with an archived replay available for 30 days post-event. iTeos is developing innovative immuno-oncology therapeutics, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing the immune response against cancer.
Domain Therapeutics has appointed Dr. Xavier Leroy as Chief Scientific Officer (CSO), enhancing its leadership in immuno-oncology and GPCR programs. Previously serving as Chief Technology Officer, Dr. Leroy will now oversee research and the transition of the company to a clinical-stage biopharmaceutical entity. He highlights the opportunity to develop first-in-class candidates targeting new GPCRs. Dr. Leroy's extensive experience includes senior roles at Actelion Pharmaceuticals and significant contributions to raising $75M in funding for immuno-oncology projects.
iTeos Therapeutics (NASDAQ: ITOS) reported strong financial results for Q1 2022, achieving a net income of $69.6 million, or $1.96 per basic share. The company's cash reserves rose to $824 million, providing funding into 2026 for ongoing clinical trials. Key developments include the enrollment of patients in pivotal trials for EOS-448, an anti-TIGIT monoclonal antibody, and inupadenant, an A2A receptor antagonist. Enhanced evidence of target engagement in tumors was presented at the AACR 2022, fueling optimism for their innovative cancer therapies.
iTeos Therapeutics has announced promising data on its anti-TIGIT antibody, EOS-448, presented at the AACR Annual Meeting 2022. The study revealed a decrease in TIGIT-positive cells in tumor biopsies, marking a significant treatment effect. Preclinical and clinical data demonstrate EOS-448's ability to reduce suppressive immune cell populations, indicating effective engagement of FcγR. These findings support ongoing clinical trials aimed at developing EOS-448 as a potent immuno-oncology therapy for patients with advanced cancers.
iTeos Therapeutics (ITOS) has made significant strides in its immuno-oncology pipeline, reporting a cash position of $848.5 million as of December 31, 2021, ensuring funding through 2026. The company is advancing its clinical trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an A2A receptor antagonist, in collaboration with GSK. Key initiatives include multiple registration-directed trials and triplet regimen studies, signaling robust clinical development plans. In 2021, iTeos reported a net income of $214.5 million, an improvement from a net loss the previous year.
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. The presentation will focus on the company's innovative immuno-oncology therapies. A live webcast will be available on their website, with an archived replay accessible for 30 days. iTeos is advancing multiple clinical-stage programs, including EOS-448, an anti-TIGIT antibody in collaboration with GSK, and inupadenant, an adenosine A2A receptor antagonist.
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Michel Detheux, will participate in two investor conferences on February 17, 2022. The 11th Annual SVB Leerink Global Healthcare Conference at 12:00 p.m. ET and Citi’s 2022 Virtual Immuno-Oncology Summit at 1:30 p.m. ET are the events scheduled for the same day. The company focuses on developing advanced immuno-oncology therapeutics, including its leading product candidates EOS-448 and inupadenant. A live webcast will be hosted on its website, with recordings available for 30 days.
iTeos Therapeutics (Nasdaq: ITOS) announced its clinical development plan for EOS-448, an anti-TIGIT monoclonal antibody, and inupadenant, an A2A receptor antagonist. The company is progressing with 11 clinical studies, including three planned registration-directed trials. EOS-448 is being investigated in combination therapies with anti-PD-1 agents, while inupadenant is evaluated with chemotherapy and pembrolizumab. Yvonne McGrath has been promoted to chief scientific officer, crucial for advancing iTeos’s immunotherapy pipeline targeting difficult-to-treat cancers.